4 Stocks Raising The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 22 points (-0.2%) at 14,556 as of Monday, April 1, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 762 issues advancing vs. 2,184 declining with 121 unchanged.

The Health Care sector currently sits down 1.1% versus the S&P 500, which is down 0.6%. A company within the sector that increased today was Celgene Corporation ( CELG), up 1.0%. On the negative front, top decliners within the sector include Vertex Pharmaceuticals ( VRTX), down 1.6%, Thermo Fisher Scientific ( TMO), down 1.3%, Gilead ( GILD), down 1.1%, Aetna ( AET), down 1.2% and Zimmer Holdings ( ZMH), down 0.9%.

TheStreet Ratings group would like to highlight 4 stocks pushing the sector higher today:

4. Dr. Reddy Laboratories ( RDY) is one of the companies pushing the Health Care sector higher today. As of noon trading, Dr. Reddy Laboratories is up $0.57 (1.8%) to $32.92 on heavy volume Thus far, 271,213 shares of Dr. Reddy Laboratories exchanged hands as compared to its average daily volume of 215,200 shares. The stock has ranged in price between $32.78-$33.76 after having opened the day at $33.50 as compared to the previous trading day's close of $32.35.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Dr. Reddy Laboratories has a market cap of $5.5 billion and is part of the drugs industry. The company has a P/E ratio of 19.6, above the S&P 500 P/E ratio of 17.7. Shares are down 2.9% year to date as of the close of trading on Thursday. Currently there is 1 analyst that rates Dr. Reddy Laboratories a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Dr. Reddy Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Dr. Reddy Laboratories Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Valeant Pharmaceuticals International ( VRX) is up $0.78 (1.0%) to $75.80 on average volume Thus far, 696,467 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $75.17-$76.44 after having opened the day at $75.24 as compared to the previous trading day's close of $75.02.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $22.8 billion and is part of the drugs industry. Shares are up 25.5% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Valeant Pharmaceuticals International Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $2.74 (1.6%) to $179.14 on average volume Thus far, 324,831 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 726,900 shares. The stock has ranged in price between $178.51-$180.75 after having opened the day at $180.00 as compared to the previous trading day's close of $176.40.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $16.8 billion and is part of the drugs industry. The company has a P/E ratio of 26.1, above the S&P 500 P/E ratio of 17.7. Shares are up 3.1% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Alexion Pharmaceuticals ( ALXN) is up $1.75 (1.9%) to $93.89 on average volume Thus far, 799,198 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $91.07-$94.29 after having opened the day at $91.07 as compared to the previous trading day's close of $92.14.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $18.0 billion and is part of the drugs industry. The company has a P/E ratio of 72.0, above the S&P 500 P/E ratio of 17.7. Shares are down 1.7% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Drug Companies Respond to States Generic Drug Lawsuit

Drug Companies Respond to States Generic Drug Lawsuit

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Changing Landscape for Generic-Drug Makers Creates Opportunities

Changing Landscape for Generic-Drug Makers Creates Opportunities

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume